Guggenheim Has Lowered Expectations for Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price

Monte Rosa Therapeutics (NASDAQ:GLUE) had its target price dropped by equities research analysts at Guggenheim from $34.00 to $30.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s price target suggests a potential upside of 86.80% from the company’s previous close.

Several other research firms have also commented on GLUE. Zacks Research lowered shares of Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 4th. Wedbush restated an “outperform” rating and issued a $37.00 target price on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research note on Monday, December 29th. Piper Sandler reiterated an “overweight” rating and set a $37.00 price target (up from $27.50) on shares of Monte Rosa Therapeutics in a report on Wednesday, January 14th. Finally, TD Cowen reissued a “buy” rating on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 7th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.80.

Monte Rosa Therapeutics Price Performance

NASDAQ:GLUE opened at $16.06 on Wednesday. The firm has a market capitalization of $1.29 billion, a price-to-earnings ratio of -34.91 and a beta of 1.63. Monte Rosa Therapeutics has a 1 year low of $3.50 and a 1 year high of $25.77. The business has a 50 day simple moving average of $19.80 and a 200-day simple moving average of $14.76.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its earnings results on Tuesday, March 17th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.10). Monte Rosa Therapeutics had a negative net margin of 31.23% and a negative return on equity of 15.12%. The company had revenue of $2.78 million for the quarter, compared to the consensus estimate of $17.09 million. As a group, analysts expect that Monte Rosa Therapeutics will post -1.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Monte Rosa Therapeutics

In other news, CEO Markus Warmuth sold 5,466 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $17.92, for a total transaction of $97,950.72. Following the completion of the sale, the chief executive officer directly owned 613,471 shares of the company’s stock, valued at approximately $10,993,400.32. The trade was a 0.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Edmund Dunn sold 25,164 shares of the business’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $18.10, for a total transaction of $455,468.40. Following the sale, the insider directly owned 22,693 shares of the company’s stock, valued at $410,743.30. This represents a 52.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 36,771 shares of company stock valued at $693,692. Corporate insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Monte Rosa Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC purchased a new position in shares of Monte Rosa Therapeutics during the fourth quarter worth approximately $30,000. Nisa Investment Advisors LLC boosted its holdings in shares of Monte Rosa Therapeutics by 16.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock valued at $49,000 after purchasing an additional 451 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in Monte Rosa Therapeutics by 32.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock worth $50,000 after purchasing an additional 776 shares in the last quarter. Seven Fleet Capital Management LP bought a new position in Monte Rosa Therapeutics in the fourth quarter worth approximately $63,000. Finally, Russell Investments Group Ltd. purchased a new position in Monte Rosa Therapeutics during the 3rd quarter worth $32,000. 79.96% of the stock is owned by hedge funds and other institutional investors.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.